Erratum: First-in-Class Anti-Immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors (Clin Cancer Res (2022) 28 (57–70) DOI: 10.1158/1078-0432.CCR-21-2160)

Lillian L. Siu, Ding Wang, John Hilton, Ravit Geva, Drew Rasco, Ruth Perets, Anson K. Abraham, Douglas C. Wilson, Julia F. Markensohn, Jared Lunceford, Leah Suttner, Shabana Siddiqi, Rachel A. Altura, Corinne Maurice-Dror

Research output: Contribution to journalComment/debate

Abstract

In the original version of this article (1), the number of patients who had ORR to MK-4830 + pembrolizumab was correct in Table 2 (n = 8), but footnote "b"contained incorrect information regarding cancer types and the number of patients with each cancer type. The error has been corrected in the latest online HTML and PDF versions of the article. The authors regret the error.

Original languageEnglish
Pages (from-to)1734
Number of pages1
JournalClinical Cancer Research
Volume28
Issue number8
DOIs
StatePublished - 15 Apr 2022

Fingerprint

Dive into the research topics of 'Erratum: First-in-Class Anti-Immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors (Clin Cancer Res (2022) 28 (57–70) DOI: 10.1158/1078-0432.CCR-21-2160)'. Together they form a unique fingerprint.

Cite this